Barbora De Courten (Associate Professor at Monash University, Melbourne, Australia) discusses the latest studies into carnosine supplementation in diabetes prevention at ADA 2018. Carnosine is food supplement and has been shown in animal studies to prevent and be useful in the treatment of type 2 diabetes. It has been show to have anti-inflammatory, anti-oxidative, and anti-advanced glycation end product properties that are important mechanisms in type 2 diabetes and related diseases. The study presented at this meeting showed the effect of carnosine supplementation on cardiometabolic risk factors in obesity, prediabetes and diabetes.
1. What is carnosine? (0:14)
2. What is the rationale behind its use in the prevention of diabetes? (0:35)
3. What are the key findings of your study around the effect of carnosine supplementation on cardiometabolic risk factors in obesity, prediabetes and diabetes? (1:21)
4. What are the key challenges in preventing diabetes? (1:49)
Filmed at ADA 2018, Orlando, FL, US
Share this Video
Related Videos In Diabetes
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!